Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)589-863
Number of pages275
JournalJournal of Clinical Oncology
Volume32
Issue number8
Publication statusPublished - Mar 10 2014

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this